Skip to main content

Table 2 Effect of tranexamic acid on vascular occlusive events (fatal and non-fatal) at 28 days in all patients, stratified by severity and country income level

From: Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial

 

TXA

Placebo

RR (95% CI)

N

n

(%)

N

n

(%)

 

All patients

6359

101

(1.6)

6280

102

(1.6)

0.98 (0.74–1.28)

Severity

Mild/moderate

4066

41

(1.0)

3997

52

(1.3)

0.76 (0.52–1.16)

Severe

2264

60

(2.7)

2247

50

(2.2)

1.19 (0.82–1.73)

Country income

LMIC

4375

50

(1.1)

4330

35

(0.8)

1.41 (0.92–2.17)

HIC

1984

51

(2.6)

1950

67

(3.4)

0.75 (0.52–1.07)